Comparative efficacy and safety of Chinese patent medicines of iron deficiency anemia during pregnancy:A network meta-analysis

BACKGROUND Iron deficiency anemia(IDA)is a prevalent nutritional disorder during pregnancy.Clinical studies indicate that incorporating Chinese patent medicines(CPMs)with oral iron(OI)in treating IDA in pregnancy can reduce adverse effects and improve clinical outcomes.Nonetheless,the comparative efficacy of different CPMs remains unclear.AIM To assess the safety and effectiveness of different CPMs for treating IDA during pregnancy using network meta-analysis.METHODS We conducted a search for randomized controlled trials(RCTs)that combined CPM and OI for IDA treatment in pregnancy,spanning from 2013 to the present.Data analysis was performed using Rev Man 5.3 and Stata 14.0 on literature that satisfied the quality criteria.RESULTS The analysis included 45 RCTs,encompassing 4422 pregnant patients with IDA.Six CPMs were examined,including Shengxuebao Mixture,Shengxuening Tablets(SXN),Yiqi Weixue CPMs(YQWX),Jianpi Shengxue CPMs(JPSX),Yiqi Buxue Tablets,and Compound Hongyi Buxue Oral Liquid(FFHY).Findings indicated that FFHY+OI significantly improved the clinical effective rate.SXN+OI was most effective in boosting red blood cells counts and hemoglobin levels.YQWX+OI showed superior results in improving serum ferritin,and SXN+OI was most effective in increasing serum iron levels.JPSX+OI was optimal in reducing adverse pregnancy outcomes,while YQBX+OI effectively minimized adverse events.A cluster analysis suggested that SXN+OI could be the potentially optimal therapeutic regimen for IDA in pregnancy.CONCLUSION This study demonstrates that the combination of OI with CPMs offers better outcomes than OI alone.Based on clinical efficacy and other measured outcomes,SXN+OI emerges as the most effective treatment modality for improving the health of pregnant patients with IDA.

Efficacy and safety of oral Chinese patent medicine combined with sacubitril/valsartan in the treatment of chronic heart failure:A Metaanalysis

Objective:To systematically evaluate the clinical efficacy of oral Chinese patent medicine combined with sacubitril/valsartan in treating chronic heart failure(CHF).Methods:CNKI,CSPD,CCD,CBM,PubMed,Web of Science,Cochrane Library and EMbase were retrieved to screen out randomized controlled trials Chinese patent medicine and Western medicine in treating CHF.Manual retrieval was also applied as a supplement.The Cochrane Reviewers Handbook 5.1.0 was used to evaluate the bias risk of the included studies and RevMan 5.4 software was used for Meta-analysis.Results:A total of 1301 patients enrolled in the 13 RCTs were included.According to the results of Meta-analysis,a combination of oral Chinese patent medicine and sacubitril/valsartan could further improve total effectiveness rate(RR=1.23,95%CI[1.16,1.30],P<0.001),increase 6 minutes’walk distance(MD=53.04,95%CI[33.43,72.64],P<0.001),improve left ventricular ejection fraction(MD=6.67,95%CI[5.15,8.19],P<0.001)and stroke volume(MD=7.56,95%CI[3.94,11.18],P<0.001),reduce left ventricular end-diastolic dimension(MD=-3.68,95%CI[-4.57,-2.78],P<0.001)and N terminal pro B type natriuretic peptide(MD=-434.08,95%CI[-518.95,-349.22],P<0.001)and no statistically significant difference in drug safety was found between the sacubitril/valsartan-only group and the combined treatment group(RR=0.73,95%CI[0.32,1.65],P=0.45).Conclusion:It’s indicated that a combination of traditional Chinese patent medicine and sacubitril/valsartan had a good clinical efficacy in the treatment of CHF,which had certain guiding significance for clinical practice.

Screening test for anti-Helicobacter pylori activity of traditional Chinese herbal medicines

AIM:To evaluate the anti-Helicobacter pylori (H.pylori) activity of 50 traditional Chinese herbal medicines in order to provide the primary evidence for their use in clinical practice.METHODS:A susceptibility test of water extract from 50 selected traditional Chinese herbal medicines for in vitro H.pylori Sydney strain 1 was performed with broth dilution method.Anti-H.pylori activity of the selected Chinese herbal medicines was evaluated according to their minimum inhibitory concentration (MIC).RESULTS:The water extract from Rhizoma Coptidis,Radix Scutellariae and Radix isatidis could significantly inhibit the H.pylori activity with their MIC less than 7.8 mg/mL,suggesting that traditional Chinese herbal medicines have anti-inflammatory and antibacterial effects and can thus be used in treatment of H.pylori infection.CONCLUSION:Rhizoma Coptidis,Radix Scutellariae and Radix isatidis are the potential sources for the synthesis of new drugs against H.pylori.

Near-Infrared Spectroscopy Combined with Absorbance Upper Optimization Partial Least Squares Applied to Rapid Analysis of Polysaccharide for Proprietary Chinese Medicine Oral Solution

Near-infrared (NIR) spectroscopy was applied to reagent-free quantitative analysis of polysaccharide of a brand product of proprietary Chinese medicine (PCM) oral solution samples. A novel method, called absorbance upper optimization partial least squares (AUO-PLS), was proposed and successfully applied to the wavelength selection. Based on varied partitioning of the calibration and prediction sample sets, the parameter optimization was performed to achieve stability. On the basis of the AUO-PLS method, the selected upper bound of appropriate absorbance was 1.53 and the corresponding wavebands combination was 400 - 1880 & 2088 - 2346 nm. With the use of random validation samples excluded from the modeling process, the root-mean-square error and correlation coefficient of prediction for polysaccharide were 27.09 mg·L-1 and 0.888, respectively. The results indicate that the NIR prediction values are close to those of the measured values. NIR spectroscopy combined with AUO-PLS method provided a promising tool for quantification of the polysaccharide for PCM oral solution and this technique is rapid and simple when compared with conventional methods.

Network-meta analysis of 9 kinds of patent Chinese medicine for nourishing qi and activating blood in the treatment of angina pectoris of coronary heart disease

Objective:To evaluate the efficacy and safety of Yiqi Huoxue oral Chinese patent medicine in the treatment of angina pectoris.Methods:the databases of EMBASE,PubMed,CNKI,Wanfang and VIP were searched by computer,and the randomized controlled trial(RCT)of Yiqi Huoxue Chinese patent medicine in the treatment of angina pectoris of coronary heart disease(CHD)was searched until December 2019.By using stata15.1 software,the total clinical effective rate,the improvement rate of ECG,the improvement rate of angina pectoris,the attack frequency and duration of angina pectoris were taken as the outcome indicators for network meta analysis and mapping.Results:51 RCTs were included,including 9 kinds of traditional Chinese medicine.The results of network meta analysis showed that:in terms of clinical total effective rate,the order was Shexiang Baoxin Pill(78.2%)>xueshuanxinming tablet>Dengzhan Shengmai capsule>Shengui Capsule>Tongxinluo capsule>Tongmai Yangxin pill>Yangxin tablet>Shexiang Tongxin drop pill>Naoxintong capsule;the improvement of ECG was Tongmai Yangxin pill(85.2%)>Yangxin tablet>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Shexiang Baoxin Pill>Tongxinluo gum Capsule>Shengui Capsule>Naoxintong capsule;in order to reduce the frequency and duration of angina pectoris,they are conventional Naoxintong capsule(88.6%)>Shengui Capsule>Tongmai Yangxin pill>Shexiang Baoxin Pill>xueshuanxinmingpian>Tongxinluo capsule>Shexiang Tongxin drop pill>Dengzhan Shengmai capsule;Shexiang Baoxin Pill(66.9%)>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Tongxinluo capsule>xueshuanxinmingning capsule Tablet>Tongmai Yangxin pill.Conclusion:Traditional Chinese medicine combined with western medicine has obvious advantages in the treatment of angina pectoris.Shexiang Baoxin Pill,Dengzhan Shengmai capsule and Tongmai Yangxin pill can be given priority.

Clinical research progress of oral administration of traditional Chinese medicine in the treatment of dry eyes

Dry eye is a common and frequently occurring ophthalmology disease with complex etiology and easy recurrence.Oral administration of traditional Chinese medicine has the characteristicsof high curative effect and little toxic and side effect in the treatment of dry eye.This paper collates the domestic reported clinical studies on the oral administration of traditional Chinese medicine in the treatment of dry eye,which are discussed from four aspects:special prescription for specific disease,addition and subtraction of main prescription,treatment based on syndrome differentiation and proprietary Chinese medicine.The curative effect and advantages of traditional Chinese medicine in the treatment of dry eye are demonstrated,providing a reference for the treatment of dry eye in the future.

Trains of Thought in Treating Infectious Atypical Pneumonia with Integrative Chinese and Western Medicine Approach

EDITORIAL Severe Acute Respiratory Syndrome(SARS)is a new intractable disease worldwide,itsonset is acute,its infectivity and mortality is high,the knowledge about its etiology and pathogenesis is in-sufficient,the experience on SARS treatment awaits accumulation.Following pilot experiences of applyingICWM in fighting SARS is most valuable with scientific significance.

Varieties of Chinese Traditional Medicines Protected by the State (Part One)

Approved by the Ministry of Public Health,the following Medicines,producedby the named enterprises,are listed as varieties of Chinese traditionalmedicines that are protected by the state.

Treatment of Irritable Bowel Syndrome by Oral Administration of Chinese Medicines and Retention-Enema——A Report of 50 Cases

Irritable bowel syndrome (IBS), a common disease of intestinal dysfunction, is also called emotional enteritis, mucous enteritis, irritable colon and so on1. It is often lingering with a long disease course and is easy to recur. The author has in recent years treated 50 cases of the disease by oral administration of Chinese medicines and retention-enema, with satisfactory results reported as follows.

Therapeutic Effect of Oral Administration and External Therapy of Traditional Chinese Medicine on Cervical Tuberculous Lymphadenopathy

Objective:To analyze the clinical effect and value of oral administration and external therapy of traditional Chinese medicine for treatment of cervical tuberculous lymphadenopathy.Methods:A total of 56 patients with cervical tuberculous lymphadenopathy admitted to our hospital from January 1 to January 2018 were recruited.By using double-blind method,the patients were divided into control group(n=28)and experimental group(n=28).Control group comprised of patients with conventional anti-tuberculosis treatment,while the experimental group comprised of patients treated with oral administration and external therapy of traditional Chinese medicine.Total effective rate,incidence of complication and level of T lymphocyte subsets were compared between the two groups of cervical tuberculous lymphadenopathy patients.Results:Post-treatment data of total effective rate,complication rate,CD3+,CD4+,CD8+,CD4+/CD8+of the experimental group were compared with the control group.P<0.05;statistical analysis showed statistical significance.Post-treatment data of CD3+,CD4+,CD8+,CD4+/CD8+of both control and experimental groups were compared with pre-treatment data.P<0.05;statistical analysis showed statistical significance.Conclusion:Oral administration and external therapy of traditional Chinese medicine possesses significant effect in treatment of cervical tuberculous lymphadenopathy.

Antimicrobial Activity of Traditional Chinese Medicines on Common Oral Bacteria

Objective: To evaluate twenty Traditional Chinese Medicines (TCM) against four oral bacteria. Methods: Twenty TCM were tested for sensitivity against Streptococcus mitis, Streptococcus sanguis, Streptococcus mutans and Porphyromonas gingivalis. Aliquots of suspension of each bacterial species were inoculated on a horse blood agar (HBA) plate, 6 mm diameter paper disks was soaked in different drug suspensions were placed concentrically on a HBA plate. Disks soaked in 0.2% w/v chlorhexidine were used as positive controls. These HBA plates were incubated for 48 hours anaerobically and the diameters of growth inhibition of three different areas were measured using a calibrated computer software and the mean diameter obtained for each bacteria. Broth microdilution assay was used to determine minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). The experiment was repeated on three separate occasions. Results: The TCMs that consistently against Porphyromonas gingivalis, included Folium artemisiae argyi, Fructus crataegi, Rhizoma dryopteris crassirhizomae, Flos magnoliae, Rhizoma polygoni cuspidati, Radix scrophulariae ningpoensis, Galla chinensis, Radix scutellariae baicalensis and Rhizoma coptidis;against Streptococcus mutans included Fructus crataegi, Galla chinensis and Rhizoma copitidis;against Streptococcus mitis and Streptococcus sanguis included Galla chinensis and Rhizoma copitidis. Conclusion: Rhizoma copitidis and Galla chinensis had inhibitory effects on Streptococcus mitis, Streptococcus sanguis, Streptococcus mutans and Porphyromonas gingivalis in vitro.

A meta-analysis of the efficacy of traditional Chinese medicine alone in the treatment of refractory gastroesophageal reflux disease

Background:To systematically evaluate the efficacy and safety of traditional Chinese medicine in the treatment of refractory gastroesophageal reflux.Methods:PubMed,The Cochrane Library,Embase,Web of Science,China National Knowledge Infrastructure,Wanfang Database,China Science and Technology Journal Database and Chinese BioMedical Literature Database were searched for randomized controlled trials of traditional Chinese medicine in the treatment of refractory gastroesophageal reflux from database establishment time to December 2020.After two researchers independently screened the literature,extracted data and evaluated the bias risk included in the study,RevMan5.3 software was used for meta-analysis.Results:A total of 12 randomized controlled trials,were included,including 893 patients.The results of meta-analysis showed that the total effective rate of the treatment group(relative risk=1.28,95%confidence interval(CI)(1.19,1.38),P<0.00001),RGERDQ(refractory gastroesophageal reflux disease)score(mean difference(MD)=−3.35,95%CI(−4.13,−2.57),P<0.00001],acid reflux(acid in the stomach comes out of the mouth)[MD=−0.30,95%CI(−0.45,−0.15),P<0.00001],heartburn(the feeling that the heart is burned)(MD=−0.44,95%CI(−0.60,−0.29),P<0.00001,and retrosternal pain(MD=−0.27,95%CI(−0.44,−0.10),P<0.00001,belching(MD=−0.40,95%CI(−0.57,−0.24),P<0.00001],endoscopic mucosal score(MD=−0.62,95%CI(−0.78,−0.46),P<0.00001],the differences were statistically significant,and the effective rate of mucosal improvement under endoscopy was P=0.93>0.05,with no statistically significant difference.Conclusion:The current evidence shows that traditional Chinese medicine in the treatment of refractory gastroesophageal reflux disease is better than that of western medicine in the total effective rate,relieving acid reflux,heartburn,retrosternal pain and belching symptoms,but it is impossible to judge the improvement of mucosa under endoscope.Due to the limitations of the quality and quantity of included studies,more high-quality studies are needed to confirm the above conclusions.

托里透毒汤口服联合紫草纱条引流促进肛周脓肿术后创面愈合的研究

目的探讨托里透毒汤方口服联合紫草纱条创面引流促进肛周脓肿患者术后创面愈合和影响炎性因子表达研究。方法选取医院2019年6月—2022年1月收治的174例肛周脓肿术的患者为研究对象,随机分为观察组(58例)、对照组A(58例)和对照组B(58例),术后所有患者给予常规处理,对照组A增加紫草纱条创面引流治疗,对照组B增加凡士林纱条创面引流治疗,观察组增加托里透毒汤方口服与紫草纱条创面引流联合治疗。比较3组患者术后第1、7、14天时疼痛程度、创面症状评分、创面愈合情况、炎性因子水平及治疗效果。结果术后第7、14天观察组血清P物质(Substance P,SP)、五羟色胺(5-Hydroxytryptamine,5-HT)水平均低于对照组A与对照组B(P<0.05),对照组A第7、14天各水平均低于对照组B(P<0.05);术后第7、14天观察组分泌物评分、水肿评分均低于对照组A与对照组B(P<0.05),对照组A7 d、14 d各评分均低于对照组B(P<0.05);观察组第7、14天创面缩小率高于对照组A与对照组B(P<0.05),对照组A第7、14天缩小率均高于对照组B,治疗后观察组创面腐肉全部脱落时间与创面愈合时间均短于对照组A与对照组B(P<0.05),对照组A各时间均低于对照组B(P<0.05);术后第7、14天观察组血清肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)、C反应蛋白(C-reactive Protein,CRP)及白细胞介素-6(Interleukin-6,IL-6)炎性因子水平均低于对照组A与对照组B(P<0.05),对照组A第7天、14天各水平均低于对照组B(P<0.05);治疗后观察组患者总有效58例(100.00%)显著比对照组A患者54例(93.10%)和对照组B患者50例(86.21%)高(P<0.05),对照组A总有效率比对照组B高,但两组比较差异不存在统计学意义(P>0.05)。结论托里透毒汤口服联合紫草纱条创面引流可以促进术后创面愈合,降低炎性因子水平,缩短康复进程,值得推广。

脑血疏口服液治疗中风临床应用专家共识

脑血疏口服液具有益气、活血、化瘀的功效,临床上广泛用于气虚血瘀所致中风的治疗。经多年临床观察,其对出血性中风、缺血性中风等有明显疗效,受到多个指南、共识及丛书的推荐。在总结临床医生应用经验的基础上,结合现有循证证据,遵照《中华中医药学会中成药临床应用专家共识报告规范》等,在问卷调查和文献系统回顾的基础上,基于现有最佳证据,充分结合专家经验,遵循“循证为主,共识为辅,经验为鉴”的原则,通过名义组法共达成16条推荐意见/共识建议,提出了脑血疏口服液治疗中风的用药时机、临床疗效、用法用量、疗程等,并说明了临床应用的安全性。该共识适用于各级医疗机构的医师在使用脑血疏口服液时作为用药参考。旨在提高脑血疏口服液治疗中风的临床疗效,促进合理用药,减少用药风险。共识已通过中华中医药学会的审核,并进行了发布,编号GS/CACM 331-2023。

活血化瘀类中药饮片与口服抗凝血药联合应用的出血风险研究

目的:探讨联合应用活血化瘀类中药饮片与口服抗凝血药治疗疾病的出血风险。方法:回顾性研究2022年该院服用口服抗凝血药和活血化瘀类中药饮片的住院患者158例,根据是否联合应用活血化瘀类中药饮片分为联合组(80例)和对照组(78例)。对照组患者使用的口服抗凝血药包括华法林、利伐沙班、达比加群酯;联合组患者联合应用的活血化瘀类中药饮片包括丹参、川芎、牛膝等。观察两组患者的凝血功能相关指标如凝血酶原时间-国际标准化比值(PT-INR)、纤维蛋白原(FIB)、D-二聚体(D-D)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)和出血事件发生率等。结果:联合组与对照组患者PT-INR、FIB、D-D、APTT和TT的差异均无统计学意义(P>0.05);联合组患者的出血事件发生率为66.25%(53/80),高于对照组的42.31%(33/78),差异有统计学意义(P<0.05)。结论:患者联合应用活血化瘀类中药饮片与口服抗凝血药后,虽然相关凝血指标并未出现明显变化,但是出血事件发生率显著升高。临床用药时,需重点关注含有丹参、川芎、牛膝和红花等的活血化瘀类中药饮片或中药复方制剂与口服抗凝血药联合应用会增加出血的风险。本研究为中西药相互作用研究提供了一定的借鉴。

炙甘草汤对顽固性复发性口腔溃疡患者的疗效研究

目的探讨炙甘草汤对顽固性复发性口腔溃疡患者的疗效。方法按照随机数字表法分配原则将196例2019年1月—2021年12月该院收治的复发性口腔溃疡患者分为对照组(98例)和治疗组(98例)。对照组给予复合维生素B片、维生素C片、西地碘片进行治疗,治疗组在对照组基础上给予炙甘草汤进行治疗,两组均持续治疗2周,并随访1年。比较两组治疗2周后的疗效,临床症状改善情况及复发情况,治疗前、治疗2周后的中医证候积分、疼痛程度、睡眠质量、生活质量、炎症、免疫指标水平及治疗期间的安全性情况。结果与对照组治疗2周后的总有效率(84.69%,83/98)比较,治疗组总有效率更高(93.88%,92/98)(P<0.05)。与对照组比较,治疗组溃疡疼痛改善时间、溃疡愈合时间更短(P<0.05);与对照组随访期间的总复发率比较(13.27%,13/98),治疗组总复发率(5.10%,5/98)更低(P<0.05)。治疗2周后,两组溃疡隐痛、反复发作、口干口苦、胃脘痞闷、视觉模拟评分法(VAS)、匹兹堡睡眠质量量表(PSQI)评分、全血CD_(8)^(+)、血清肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)水平与治疗前比较降低,治疗组更低(P<0.05);两组生存质量测定量表(QOL-100)评分、全血CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)水平与治疗前比较升高,治疗组更高(P<0.05)。治疗组和对照组治疗期间均未发生恶心呕吐、皮疹、头晕等情况。结论炙甘草汤可有效调节顽固性复发性口腔溃疡患者炎症及免疫指标水平,减轻机体炎症,改善免疫功能,并可改善疼痛程度、睡眠和生活质量,进而可促进患者中医证候及临床症状的改善,预防复发,疗效显著,安全性良好。

从虚论治慢性复发性口腔溃疡

口腔溃疡是一种常见的口腔黏膜溃疡损伤性疾病。该病病因复杂,复发率高,对患者的饮食、说话等均有一定影响。以20年的临床经验为基础,通过辨证、辨体、辨病的中医辨证方法,认识到该病多为“上虚不足”,导致反复发作,并通过补虚升提的方法治疗,取得了较好的效果。

中药口服联合艾灸治疗溃疡性结肠炎疗效及安全性的Meta分析

目的 基于Meta分析评价中药口服联合艾灸治疗溃疡性结肠炎(UC)的临床疗效及安全性。方法 通过计算机检索中国知网、万方数据知识服务平台、维普网和PubMed,收集中药口服联合艾灸治疗UC的临床随机对照试验,检索时间为建库至2022年11月30日。试验组给予中药口服+艾灸治疗或联合常规西药治疗,对照组给予常规西药治疗。由研究人员对收集的文献进行筛选、资料提取,并使用Review Manager 5.4软件进行Meta分析。结果 最终纳入12篇符合标准的文献,共包含1 055例患者,试验组534例,对照组521例。Meta分析结果显示,试验组总有效率高于对照组[OR=3.83,95%CI(2.65,5.53),P<0.000 01]。根据试验组干预方法的不同进行亚组分析:中药口服+艾灸组总有效率高于对照组[OR=3.80,95%CI(2.47,5.85),P<0.000 01];中药口服+艾灸联合常规西药组总有效率高于对照组[OR=3.91,95%CI(1.93,7.91),P=0.000 2]。试验组复发率低于对照组[OR=0.23,95%CI(0.07,0.71),P=0.01]。试验组不良反应发生率低于对照组[OR=0.39,95%CI(0.19,0.78),P=0.007]。结论 中药口服联合艾灸治疗UC可提高总有效率,降低复发率,且不良反应较少。

干燥综合征的中西医结合护理进展

干燥综合征(SS)是一种以泪腺和唾液腺的淋巴细胞浸润,伴有干燥性角膜结膜炎及口腔干燥为主要临床表现的免疫反应介导疾病,临床上分为原发性和继发性。本文主要对SS相关中西医结合护理进行总结,主要包括各器官、皮肤、呼吸道护理、饮食干预等,对SS患者给予心理指导,保证护理措施的正确性、系统性,提高SS患者及家属对疾病的认知,建立患者治疗信心,临床中医护人员需积极主动配合,保证治疗、护理工作顺利开展,最终改善患者生命质量。

七味三七口服液辅助中药外洗治疗对髋关节置换手术患者术后患肢疼痛及肿胀情况的影响

目的 研究七味三七口服液辅助中药外洗治疗对髋关节置换手术患者术后患肢疼痛、肿胀情况的影响。方法 选取四川省骨科医院2021年6月至2022年6月行髋关节置换手术患者共120例。采用随机数字表法分为观察组和对照组,各60例。观察组患者术后予中药外洗、七味三七口服液治疗,对照组患者予术后常规治疗。比较2组中医证候积分、疼痛因子水平、患肢肿胀及不良反应发生情况。结果 治疗后,2组粗肿、胀痛、皮温升高、皮色改变中医证候积分均低于治疗前,且观察组均低于对照组(均P<0.05);2组β-内啡肽水平均高于治疗前,且观察组高于对照组,而2组前列腺素E2、5-羟色胺水平和视觉模拟量表评分均低于治疗前,且观察组均低于对照组(均P<0.05)。术后第3、7天,2组肿胀值均降低,且观察组均低于对照组[(0.63±0.21)cm比(0.75±0.24)cm、(0.47±0.12)cm比(0.66±0.17)cm](均P<0.05)。观察组不良反应发生率低于对照组(P<0.05)。结论 七味三七口服液辅助中药外洗可有效缓解髋关节置换手术患者术后患肢疼痛和肿胀,降低恶心、呕吐等不良反应发生的可能性,促进术后恢复。